Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Naoto Takahashi, MD PhD FJSIM, Tetsuzo Tauchi, MDPhD, Kunio Kitamura, MD PhD, Koichi Miyamura, MD PhD, Yoshio Saburi, MD PhD, Yasuhiko Miyata, MD PhD, Yoshihiro Hatta, Fumihiko Kimura, MD, Satoru Takada, MD, Tetsuya Fukuda, MD PhD, Katsumichi Fujimaki, Maho Ishikawa, Itaru Matsumura, MDPhD, Noriko Usui, MD, PhD, Kensuke Usuki, MDPhD, Yukio Kobayashi, MD PhD, Tomoki Naoe, MD PhD

Blood (2015) 126 (23): 4035.

https://doi.org/10.1182/blood.V126.23.4035.4035

Published: 2015

Journal Articles

Combination of the Histone Deacetylase Inhibitor Vorinostat with a B-Cell Receptor Signaling Inhibitor Markedly Decreases Cyclin D1 Expression in a Mantle Cell Lymphoma Cell Line

Kazumi Hagiwara, PhD, Hiroatsu Iida, MD PhD, Yasuhiko Miyata, MD PhD, Tomoki Naoe, MDPhD, Hirokazu Nagai, MD PhD

Blood (2014) 124 (21): 3631.

https://doi.org/10.1182/blood.V124.21.3631.3631

Published: 2014

Journal Articles

Dose Of Vincristine didn’t Predict Outcome Of Treatment For Elderly DLBCL Patients Introductions

Yasuhiko Miyata, MD, PhD, Hiroyuki Nakamura, MD, Hideyuki Yamamoto, MD, Yuki Kojima, MD, Hiroatsu Iida, MD, PhD, Hirokazu Nagai, MD, PhD

Blood (2013) 122 (21): 5110.

https://doi.org/10.1182/blood.V122.21.5110.5110

Published: 2013

Journal Articles

Single-Institute Surveillance of Blood-Stream Infections by Stenotrophomas Maltophilia Among Patients with Hematological Diseases

Yasuhiko Miyata, MD, PhD, Yuki Kojima, MD, Hiroyuki Nakamura, MD, Hideyuki Yamamoto, MD, Hiroatsu Iida, MD, PhD, Haruhiko Ohashi, MD, PhD, Yasue Hayakawa, Tomoko Okano, Hirokazu Nagai, MD, PhD

Blood (2012) 120 (21): 4694.

https://doi.org/10.1182/blood.V120.21.4694.4694

Published: 2012

Journal Articles

Cytotoxic Effect of Bendamustine Combined with Kinase Inhibitors in Hematologic Cell Lines

Kazumi Hagiwara, Yuki Kojima, MD, Yasuhiko Miyata, MD, PhD, Hirokazu Nagai, MD, PhD

Blood (2012) 120 (21): 4912.

https://doi.org/10.1182/blood.V120.21.4912.4912

Published: 2012

Journal Articles

Mast Cells As a Therapeutic Target for Hodgkin Lymphoma: Bortezomib Inhibits Mast Cell-Induced Modification of the Tumor Microenvironment

Hiroki Mizuno, MD, Takayuki Nakayama, MD, PhD, Yasuhiko Miyata, MD, PhD, Shigeki Saito, MD, PhD, Nishiwaki Satoshi, MD, PhD, Norihiko Nakao, Kyosuke Takeshita, Akihiro Tomita, MD, Ph.D., Tomoki Naoe, MD, PhD

Blood (2012) 120 (21): 3634.

https://doi.org/10.1182/blood.V120.21.3634.3634

Published: 2012

Journal Articles

Phase I Study of Clofarabine (JC0707) in Adult Japanese Patients with Acute Myeloid Leukemia (AML)

Takahiro Yamauchi, MD, PhD, Tatsuya Suzuki, MD, PhD, Kiyoshi Ando, MD, PhD, Tadashi Nagai, MD, PhD, Kazuhiko Kakihana, MD, PhD, Yasuhiko Miyata, MD, PhD, Reginald Ewesuedo, MD, Yasuhiro Tabata, MD, PhD, Michinori Ogura

Blood (2011) 118 (21): 4295.

https://doi.org/10.1182/blood.V118.21.4295.4295

Published: 2011

Journal Articles

Prox1 Suppressed Tumor Cell Growth by the Down Regulation of PKCβII Through the DNA Methylation

Kazumi Hagiwara, Takashi Murate, MD, Yasuhiko Miyata, MD, PhD, Tomomitsu Hotta, MD, PhD, Hirokazu Nagai, MD, PhD

Blood (2011) 118 (21): 5227.

https://doi.org/10.1182/blood.V118.21.5227.5227

Published: 2011

Journal Articles

PAX5-PML Acts as a Dual Dominant-Negative Form of PAX5 and PML

Shingo Kurahashi, MD, Fumihiko Hayakawa, MD, PhD, Yasuhiko Miyata, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 3227.

https://doi.org/10.1182/blood.V116.21.3227.3227

Published: 2010

Journal Articles

Akt-Mediated Phosphorylation of Bmi1 Regulates Its Chromatin Association and Growth Promoting Properties.

Yan Liu, Fan Liu, Ph.D., Xinyang Zhao, Goro Sashida, Anthony Deblasio, Zhenbang Chen, Hui-kuan Lin, Silvana Di Giandomenico, Shannon Elf, Youyang Yang, Yasuhiko Miyata, MD, PhD, Gang Huang, Ph.D., Silvia Menendez, Ingo Mellinghoff, MD, Pier Paolo Pandolfi, MD, PhD, Cyrus V. Hedvat, MD, PhD, Stephen D. Nimer

Blood (2009) 114 (22): 3605.

https://doi.org/10.1182/blood.V114.22.3605.3605

Published: 2009

Journal Articles

PAX5-PML Acts as a Dual Dominant-Negative Form of Both PAX5 and PML.

Shingo Kurahashi, MD, Fumihiko Hayakawa, MD, PhD, Yasuhiko Miyata, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2009) 114 (22): 3070.

https://doi.org/10.1182/blood.V114.22.3070.3070

Published: 2009

NARROW

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Combination of the Histone Deacetylase Inhibitor Vorinostat with a B-Cell Receptor Signaling Inhibitor Markedly Decreases Cyclin D1 Expression in a Mantle Cell Lymphoma Cell Line

Dose Of Vincristine didn’t Predict Outcome Of Treatment For Elderly DLBCL Patients Introductions

Single-Institute Surveillance of Blood-Stream Infections by Stenotrophomas Maltophilia Among Patients with Hematological Diseases

Cytotoxic Effect of Bendamustine Combined with Kinase Inhibitors in Hematologic Cell Lines

Mast Cells As a Therapeutic Target for Hodgkin Lymphoma: Bortezomib Inhibits Mast Cell-Induced Modification of the Tumor Microenvironment

Phase I Study of Clofarabine (JC0707) in Adult Japanese Patients with Acute Myeloid Leukemia (AML)

Prox1 Suppressed Tumor Cell Growth by the Down Regulation of PKCβII Through the DNA Methylation

PAX5-PML Acts as a Dual Dominant-Negative Form of PAX5 and PML

Akt-Mediated Phosphorylation of Bmi1 Regulates Its Chromatin Association and Growth Promoting Properties.

PAX5-PML Acts as a Dual Dominant-Negative Form of Both PAX5 and PML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only